CMS Open Payments · Program Year 2024
Bioprotect Ltd.
Bioprotect Ltd. reported $222,429.00 across General Payments, Research, and Ownership to 3 physicians and teaching hospitals across 8 transactions.
- $222.4K Below-median payer
- All-tracks total
- 8 Below-median volume
- Transactions
- 3 Below-median reach
- Recipients
- #973
- of 1,925 companies
Bioprotect Ltd. reported $222,429.00 across all CMS Open Payments tracks (General + Research + Ownership) to 3 physicians and teaching hospitals in Program Year 2024 - ranking #973 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $12,000.00, averaging $74.1K per recipient.
How Bioprotect Ltd.'s $222.4K all-tracks total breaks down
Bioprotect Ltd.'s payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
11/100
Total payments
F
12/100
Transaction volume
F
10/100
Physician reach
F
10/100
Payment type diversity
F
10/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer bioprotect-ltd Bioprotect Ltd.
$222.4K · #973/1,925 · 0.0% industry · PY2024
- TOT $222.4K
- RANK #973
- SHARE 0.0%
- TXN 8
- RCP 3
- CAT 1
- GEN $12.0K
- TOP1 33.3%
- PY 2024
Volume peers
Nearest volume peer: Evologics LLC ($222.2K)
Bioprotect Ltd. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
What the Data Shows for Bioprotect Ltd.
CMS Open Payments is not a single ledger: the all-tracks total shown above is General Payments plus Research Payments plus Ownership/Investment interests, each with its own disclosure rules. For Bioprotect Ltd., that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. Data for a given Program Year arrives roughly a year after the period it covers; our methodology page documents the release cadence and how we standardize the tracks for cross-company comparison.
"Consulting Fee" leads the 1-category general-payment breakdown below at $12.0K (100.0% of General Payments, 3 transactions) - see our methodology for how research and ownership payments are reported separately.
General Payment Breakdown by Type
Across 1 types of general payments, Bioprotect Ltd.'s largest category was "Consulting Fee" at $12.0K - 100.0% of General Payments.
How Bioprotect Ltd. divides its payments
Ranked by total dollars reported per category
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Consulting Fee | $12.0K | 3 | 100.0% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $12,000.00 (100.0%) of $12,000.00 in this company's General Payments records across 3 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Bioprotect Ltd.
The five named recipients with the highest reported General Payments from this company
- 1
Vishesh Agrawal
$4,000.00 across 1 reported transactions
- 2
Shawn H Zimberg
$4,000.00 across 1 reported transactions
- 3
Naima B Alexander
$4,000.00 across 1 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Bioprotect Ltd. ranks #973 of 1,925 by total payments (bottom 50% by spend) but is notably more concentrated than that alone would suggest -- #529 of 1,838 by HHI (top 29% most concentrated). Its payments land on an unusually narrow set of recipients for its spend size.
View all 12 companies in this HHI neighborhood as a list
- Nidek Incorporated : $16.8K total payments, HHI 3356
- Grifols Diagnostic Solutions, Inc. : $48.20 total payments, HHI 3353
- Roche Diabetes Care GmbH : $52.4K total payments, HHI 3353
- OrganOx Ltd : $271.0K total payments, HHI 3335
- Midwest Surgical Alliance, LLC : $994.3K total payments, HHI 3333
- Uc-Care (usa), Inc : $12.9K total payments, HHI 3333
- Bioprotect Ltd. (this company) : $12.0K total payments, HHI 3333
- Cardinal Health 414 LLC : $311.8K total payments, HHI 3320
- Ortho Organizers, Inc. : $318.5K total payments, HHI 3318
- BioFire Diagnostics, LLC : $2.6K total payments, HHI 3299
- Menarini Silicon Biosystems, Inc. : $251.9K total payments, HHI 3287
- Grace Medical, Inc. : $46.8K total payments, HHI 3285
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Bioprotect Ltd.'s, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Bioprotect Ltd..
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Bioprotect Ltd..
Showing 6 of 1,924 companies with CMS-reported payment data.
Kyowa Kirin Services Ltd
B. Braun Medical Inc.
FHC, Inc.
Joimax, Inc.
Fisher & Paykel Healthcare Inc
Put this to use
Bioprotect Ltd. ranks #973 of 1,925 by all-tracks total payments, led by "Consulting Fee".
- See how manufacturer spending compares across the full leaderboard. Top 100 by total payments
- Compare "Consulting Fee" spend across every manufacturer, not just Bioprotect Ltd.. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.